Conclusion
As evidenced by the current literature, the PIG-A mutation test is a promising tool for human biomonitoring and disease. With further technological development, test battery development and international collaboration, we expect this simple, high-throughput assay to advise us on both harmful and beneficial exposures to genotoxins and chemo-preventative agents. This will ultimately lead to improved lifestyle choices, reduced occupational hazards and even earlier diagnosis of high-risk cancer patients and other cancer associated inflammatory diseases such as IBD.